Automated Insulin Delivery Technology in the Hospital: Update on Safety and Efficacy Data

Area of Science:

• Endocrinology
• Medical Technology
• Diabetes Management

Background:

• Automated insulin delivery (AID) systems are increasingly used in continuous subcutaneous insulin infusion (CSII) therapy.
• Assessing the safety and efficacy of AID systems in the inpatient setting is crucial as their use expands.

Purpose of the Study:

• To evaluate the safety and glycemic control of AID systems in hospitalized patients.
• To compare outcomes of AID users with non-AID CSII users and those with discontinued CSII.

Main Methods:

• Retrospective analysis of 185 hospitalized patients from June 2020 to December 2022.
• Categorization into AID users, non-AID CSII users, and patients with discontinued CSII.
• Comparison of adverse events and glycemic control metrics across groups.

Main Results:

• The proportion of patients using AID systems increased over the study period.
• No adverse events, including diabetic ketoacidosis or pump complications, were reported in any CSII group.
• Glycemic control, measured by mean glucose levels and hypoglycemia, was similar across groups, with significantly lower hyperglycemia in the AID cohort.

Conclusions:

• Inpatient use of AID systems is feasible and safe, mirroring outpatient performance.
• The trend in hospital CSII technology is shifting towards AID systems.
• Further research is warranted to determine specific glycemic control advantages of AID in inpatient settings.